Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer

Nat Commun. 2018 Mar 14;9(1):1074. doi: 10.1038/s41467-018-03473-9.

Abstract

Photothermal therapy (PTT) is a promising cancer treatment modality, but PTT generally requires direct access to the source of light irradiation, thus precluding its utility against disseminated, metastatic tumors. Here, we demonstrate that PTT combined with chemotherapy can trigger potent anti-tumor immunity against disseminated tumors. Specifically, we have developed polydopamine-coated spiky gold nanoparticles as a new photothermal agent with extensive photothermal stability and efficiency. Strikingly, a single round of PTT combined with a sub-therapeutic dose of doxorubicin can elicit robust anti-tumor immune responses and eliminate local as well as untreated, distant tumors in >85% of animals bearing CT26 colon carcinoma. We also demonstrate their therapeutic efficacy against TC-1 submucosa-lung metastasis, a highly aggressive model for advanced head and neck squamous cell carcinoma (HNSCC). Our study sheds new light on a previously unrecognized, immunological facet of chemo-photothermal therapy and may lead to new therapeutic strategies against advanced cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Combined Modality Therapy / methods*
  • Doxorubicin / therapeutic use
  • Drug Therapy, Combination
  • Humans
  • Neoplasm Metastasis / drug therapy*
  • Neoplasm Metastasis / therapy*
  • Photochemotherapy / methods
  • Phototherapy / methods*

Substances

  • Doxorubicin